Veterinary Medicines

Matrix 6000 For IV treatment of lameness associated with non-infectious synovitis and degenerative joint disease

High molecular weight, high viscosity, high performance


Sodium Hyaluronate 10 mg/mL


6 x 6mL vials per outer carton
12 x 6mL vials per outer carton


Matrix 6000 IV Injection is a high molecular weight, high viscosity formulation of sodium hyaluronate. It is ideal for intravenous use in the treatment and prevention of lameness in horses due to non-infectious synovitis possibly associated with early equine degenerative joint disease.

Since this product originates from a microbial source, there is no potential for contamination with dermatan or chondroitin sulphate or any other glycosaminoglycan.


Hyaluronic Acid (HA) is a natural and essential component of articular cartilage and synovial fluid. It is produced by both synoviocytes within the synovial membrance as well as by chondrocytes within the articular cartilage matrix.

HA also constitutes the major component of the capsule of certain micro-organisms. The hyaluronic acid produced by bacteria is of the same structure and configuration as that found in mammals. It is widely accepted that sodium hyaluronate restores lubrication of the joint fluid and regulates the normal cellular constituents. This effect decreases the impact of exudation, enzyme release, and subsequent degradation of joint integrity.

HA has the ability to confer extraordinary compressive strength to the articular cartilage when functioning as the core molecule for proteoglycan aggregates. Articular surfaces are covered with a fine layer of HA, which exerts resistance to cartilage compression while still retaining its elasticity. HA also confers viscoelastic as well as lubricating properties to synovial fluid and is responsible for the boundary lubrication of synovial membrances and the lubrication of articular cartilage. These latter properties are believed to be further increased by higher molecular weight formulations of HA.

Hyaluronate molecules are long chains which form a filter matrix interspersed with normal cellular fluids. This supplements the viscoelastic properties of normal joint fluid. Sodium hyaluronate exerts a slight anti-inflammatory action by providing a steric barrier that limits the movement of granulocytes and macrophages into the joint..


Early treatment is an important step in preventing the products of inflammation from damaging articular cartilage and causing degenerative joint disease.

Radiographs should be taken prior to administration to eliminate a possible diagnosis of joint fractures or advanced degenerative joint disease..


Dosage: Adult horse (450-700 kg). Administer 4 – 6 mL (40 – 60mg) intravenously.

Treatment may be repeated at weekly intervals for a total of three treatments.

In performance horses, Matrix 6000 may be administered prior to competition as an aid in reducing joint inflammation and restoring joint function. The regulations of the relevant competition Authority regarding medication should always be observed.

To achieve best results in cases of intravenous administration, horses should be rested during treatment and given 7 days stable rest after treatment before gradually resuming normal activity.

This product does not contain any antimicrobial preservative. Any solution remaining in the vial after administration of the required dose should be discarded.


Zero (0) days


If used in performance animals, the regulations of the relevant authorities regarding medication should be observed.


If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126, New Zealand 0800 764 766.


Dispose of empty containers, outer packaging or expired product by wrapping with paper and putting in garbage. Discarded needles/sharps should immediately be placed in a designated and appropriately labelled “sharps” container.


Store below 25°C (air conditioning).

This product does not contain any antimicrobial preservative. Any solution remaining in the vial after administration of the required dose should be discarded.


APVMA Approval No. 70144/62606 (Australia)

ACVM No. A011191 (New Zealand)

© Randlab 2019 | All rights reserved